Telephone
N/A
Address
Level 14 333 Collins Street Melbourne, Victoria (VIC) 3000
Description
Adherium Ltd. engages in the development, manufacture, and supply of digital health technologies. It operates through the following geographical segments: New Zealand and Australia, South-East Asian Countries, and Other Countries. The firm's Hailie system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. The company was founded by Garth Sutherland in 2001 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.0
Trade Value (12mth)
US$1,416.00
1 week
0%
1 month
0%
YTD
-25%
1 year
-40%
All time high
0.72
EPS 3 yr Growth
-93.400%
EBITDA Margin
-366.90%
Operating Cashflow
-$9m
Free Cash Flow Return
-125.40%
ROIC
-133.30%
Interest Coverage
-1,953.50
Quick Ratio
3.30
Shares on Issue (Fully Dilluted)
4999m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
NZD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 October 22 |
Becoming a substantial holder
×
Becoming a substantial holder |
31 October 18 |
Adherium Investor Conference Call Presentation
×
Adherium Investor Conference Call Presentation |
31 August 22 |
Preliminary Final Report
×
Preliminary Final Report |
30 September 22 |
Appendix 4G
×
Appendix 4G |
30 September 22 |
Corporate Governance Statement 2022
×
Corporate Governance Statement 2022 |
30 September 22 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 September 22 |
Change in substantial holding
×
Change in substantial holding |
30 September 19 |
Annual Report to shareholders 30 June 2019
×
Annual Report to shareholders 30 June 2019 |
30 September 15 |
New Clinical Data Presented at ERS 2015
×
New Clinical Data Presented at ERS 2015 |
30 October 20 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
30 October 17 |
Investor Conference Call Presentation - with notes
×
Investor Conference Call Presentation - with notes |
30 November 23 |
CEO Presentation to the Annual General Meeting
×
CEO Presentation to the Annual General Meeting |
30 November 23 |
Results of Meeting & Approval of Share Consolidation
×
Results of Meeting & Approval of Share Consolidation |
30 November 22 |
CEO's Address to Shareholders at AGM
×
CEO's Address to Shareholders at AGM |
30 November 22 |
Results of Meeting and Director Update
×
Results of Meeting and Director Update |
30 November 20 |
Adherium CEO Presentation to AGM
×
Adherium CEO Presentation to AGM |
30 May 22 |
Adherium Senior Management Update
×
Adherium Senior Management Update |
30 January 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 August 23 |
Change of Company Address
×
Change of Company Address |
30 August 23 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 August 23 |
Appendix 4G & Corporate Governance Statement
×
Appendix 4G & Corporate Governance Statement |
30 April 21 |
EGM presentation
×
EGM presentation |
29 September 17 |
Annual Report to shareholders
×
Annual Report to shareholders |
29 November 17 |
Presentation to AGM
×
Presentation to AGM |
29 August 22 |
Application for quotation of securities - ADR
×
Application for quotation of securities - ADR |
29 August 17 |
Investor Conference Call Presentation
×
Investor Conference Call Presentation |
29 August 17 |
Investor Conference Call Presentation - with notes
×
Investor Conference Call Presentation - with notes |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.